Zymeworks ROE 2016-2022 | ZYME

Current and historical return on equity (ROE) values for Zymeworks (ZYME) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Zymeworks ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $-0.24B $0.22B -92.25%
2022-03-31 $-0.24B $0.28B -85.23%
2021-12-31 $-0.21B $0.25B -69.49%
2021-09-30 $-0.21B $0.28B -61.14%
2021-06-30 $-0.22B $0.32B -58.18%
2021-03-31 $-0.20B $0.38B -45.61%
2020-12-31 $-0.18B $0.41B -39.03%
2020-09-30 $-0.22B $0.43B -50.86%
2020-06-30 $-0.17B $0.49B -43.85%
2020-03-31 $-0.16B $0.52B -45.89%
2019-12-31 $-0.15B $0.25B -54.72%
2019-09-30 $-0.06B $0.31B -25.75%
2019-06-30 $-0.05B $0.33B -24.82%
2019-03-31 $-0.03B $0.17B -17.00%
2018-12-31 $-0.04B $0.18B -23.45%
2018-09-30 $-0.01B $0.17B -9.17%
2018-06-30 $-0.01B $0.19B -8.33%
2018-03-31 $-0.02B $0.10B -15.35%
2017-12-31 $-0.01B $0.12B -11.56%
2017-09-30 $-0.05B $0.08B -72.48%
2017-06-30 $-0.05B $0.10B -93.02%
2017-03-31 $-0.05B $0.05B -155.93%
2016-12-31 $-0.03B $0.07B -194.12%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.529B $0.412B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.076B 8.19
GSK (GSK) United Kingdom $70.106B 9.78
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.491B 22.15
Ginkgo Bioworks Holdings (DNA) United States $3.170B 0.00
Arcus Biosciences (RCUS) United States $1.611B 0.00
Biohaven (BHVN) United States $1.059B 0.00
Emergent Biosolutions (EBS) United States $0.412B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.175B 0.00
Enzo Biochem (ENZ) United States $0.114B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00